US3637701A
(en)
*
|
1969-03-03 |
1972-01-25 |
Sandoz Ag |
Certain nitrate derivatives of 4-aminoquinazolines
|
BE759842R
(fr)
*
|
1969-12-05 |
1971-06-03 |
Sandoz Sa |
Nouveaux derives de la 4-amino-quinazoline, leur preparation etmedicaments contenant ces
|
US3885035A
(en)
*
|
1972-04-05 |
1975-05-20 |
Sandoz Ag |
Method for treating arrhythmia by using 1,4-bis(4 quinazolinyl) piperazines
|
US3857944A
(en)
*
|
1972-04-21 |
1974-12-31 |
Sandoz Ag |
1-piperazinoisoquinolines as inotropic agents
|
CH583225A5
(de)
*
|
1972-09-25 |
1976-12-31 |
Sandoz Ag |
|
GB1582407A
(en)
*
|
1977-06-07 |
1981-01-07 |
Worcester Controls Uk Ltd |
Annular seals
|
US4171363A
(en)
*
|
1977-02-22 |
1979-10-16 |
Bristol-Myers Company |
1,2,3-Thiadiazole process
|
IN148482B
(de)
|
1977-06-03 |
1981-03-07 |
Pfizer |
|
US4370328A
(en)
|
1977-11-03 |
1983-01-25 |
Pfizer Inc. |
Cardiac stimulant 1-(3- or 4-substituted piperidino)phthalazines
|
CA1086735A
(en)
*
|
1977-11-03 |
1980-09-30 |
John C. Danilewicz |
Piperidino-quinazolines
|
CH651027A5
(de)
*
|
1982-11-12 |
1985-08-30 |
Sandoz Ag |
Heterocyclische verbindungen, ihre herstellung und verwendung.
|
DE3346675A1
(de)
*
|
1983-12-23 |
1985-07-04 |
Beiersdorf Ag, 2000 Hamburg |
Substituierte 1-(4-amino-6,7-dialkoxy-chinazolinyl)-4- cyclohexenyl-derivate des piperazins und homopiperazins, verfahren zu ihrer herstellung und ihre verwendung sowie diese verbindungen enthaltende zubereitungen und zwischenprodukte
|
GB8908229D0
(en)
*
|
1989-04-12 |
1989-05-24 |
Smithkline Beckman Intercredit |
Compounds
|
US5710158A
(en)
*
|
1991-05-10 |
1998-01-20 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
|
US6645969B1
(en)
|
1991-05-10 |
2003-11-11 |
Aventis Pharmaceuticals Inc. |
Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
|
US5480883A
(en)
*
|
1991-05-10 |
1996-01-02 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
|
JP2657760B2
(ja)
*
|
1992-07-15 |
1997-09-24 |
小野薬品工業株式会社 |
4−アミノキナゾリン誘導体およびそれを含有する医薬品
|
EP0669324A4
(de)
*
|
1993-09-10 |
1996-04-03 |
Eisai Co Ltd |
Chinazolin derivate.
|
IL112249A
(en)
|
1994-01-25 |
2001-11-25 |
Warner Lambert Co |
Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
|
IL112248A0
(en)
|
1994-01-25 |
1995-03-30 |
Warner Lambert Co |
Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
|
US5776962A
(en)
*
|
1994-08-03 |
1998-07-07 |
Cell Pathways, Inc. |
Lactone compounds for treating patient with precancerous lesions
|
US5696159A
(en)
*
|
1994-08-03 |
1997-12-09 |
Cell Pathways, Inc. |
Lactone compounds for treating patients with precancerous lesions
|
GB2295387A
(en)
*
|
1994-11-23 |
1996-05-29 |
Glaxo Inc |
Quinazoline antagonists of alpha 1c adrenergic receptors
|
US5658902A
(en)
*
|
1994-12-22 |
1997-08-19 |
Warner-Lambert Company |
Quinazolines as inhibitors of endothelin converting enzyme
|
US5874440A
(en)
*
|
1995-06-07 |
1999-02-23 |
Cell Pathways, Inc. |
Method of treating a patient having precancerous lesions with phenyl pyrimidinone derivatives
|
US6046206A
(en)
*
|
1995-06-07 |
2000-04-04 |
Cell Pathways, Inc. |
Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
|
US6262059B1
(en)
|
1995-06-07 |
2001-07-17 |
Cell Pathways, Inc. |
Method of treating a patient having precancerous lesions with quinazoline derivatives
|
US6232312B1
(en)
|
1995-06-07 |
2001-05-15 |
Cell Pathways, Inc. |
Method for treating patient having precancerous lesions with a combination of pyrimidopyrimidine derivatives and esters and amides of substituted indenyl acetic acides
|
US6046216A
(en)
*
|
1995-06-07 |
2000-04-04 |
Cell Pathways, Inc. |
Method of treating a patient having precancerous lesions with phenyl pyridinone derivatives
|
US6060477A
(en)
*
|
1995-06-07 |
2000-05-09 |
Cell Pathways, Inc. |
Method of treating a patient having precancerous lesions with phenyl cycloamino pyrimidinone derivatives
|
US6200980B1
(en)
|
1995-06-07 |
2001-03-13 |
Cell Pathways, Inc. |
Method of treating a patient having precancerous lesions with phenyl purinone derivatives
|
CA2238283C
(en)
*
|
1997-05-30 |
2002-08-20 |
Cell Pathways, Inc. |
Method for identifying compounds for inhibition of neoplastic lesions, pharmaceutical compositions from such compounds and uses of such compounds and compositions for treating neoplastic lesions
|
US5858694A
(en)
*
|
1997-05-30 |
1999-01-12 |
Cell Pathways, Inc. |
Method for identifying compounds for inhibition of cancerous lesions
|
US5852035A
(en)
*
|
1997-12-12 |
1998-12-22 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells and related conditions by exposure to substituted N- arylmethyl and heterocyclmethyl-1H-pyrazolo (3,4-B) quinolin-4-amines
|
DE19756388A1
(de)
*
|
1997-12-18 |
1999-06-24 |
Hoechst Marion Roussel De Gmbh |
Substituierte 2-Aryl-4-amino-chinazoline
|
US6410584B1
(en)
*
|
1998-01-14 |
2002-06-25 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells with indole derivatives
|
US6046199A
(en)
*
|
1998-01-14 |
2000-04-04 |
Cell Pathways, Inc. |
Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B]indole derivatives
|
US5942520A
(en)
*
|
1998-01-27 |
1999-08-24 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells by exposure to substituted N-cycloalkylmethyl-1-H-pyrazolo (3,4-B) quinolone-4 amines
|
US5990117A
(en)
*
|
1998-04-15 |
1999-11-23 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells and related conditions by exposure to quinazoline derivatives
|
US6124303A
(en)
*
|
1998-09-11 |
2000-09-26 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells and related conditions by exposure to 9-substituted 2-(2-N-aloxyphenyl) purin-6-ones
|
US6268372B1
(en)
|
1998-09-11 |
2001-07-31 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones
|
US6130053A
(en)
*
|
1999-08-03 |
2000-10-10 |
Cell Pathways, Inc. |
Method for selecting compounds for inhibition of neoplastic lesions
|
US6200771B1
(en)
|
1998-10-15 |
2001-03-13 |
Cell Pathways, Inc. |
Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
|
IT1302677B1
(it)
|
1998-10-15 |
2000-09-29 |
Zambon Spa |
Derivati benzazinici inibitori della fosfodiesterasi 4
|
US6133271A
(en)
*
|
1998-11-19 |
2000-10-17 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
|
US6187779B1
(en)
|
1998-11-20 |
2001-02-13 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
|
US6369092B1
(en)
|
1998-11-23 |
2002-04-09 |
Cell Pathways, Inc. |
Method for treating neoplasia by exposure to substituted benzimidazole derivatives
|
US6077842A
(en)
*
|
1998-11-24 |
2000-06-20 |
Cell Pathways, Inc. |
Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
|
US6486155B1
(en)
|
1998-11-24 |
2002-11-26 |
Cell Pathways Inc |
Method of inhibiting neoplastic cells with isoquinoline derivatives
|
US6034099A
(en)
*
|
1998-11-24 |
2000-03-07 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
|
US6025394A
(en)
|
1999-01-29 |
2000-02-15 |
Cell Pathways, Inc. |
Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols
|
US6020379A
(en)
*
|
1999-02-19 |
2000-02-01 |
Cell Pathways, Inc. |
Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
|
US6080747A
(en)
|
1999-03-05 |
2000-06-27 |
Hughes Institute |
JAK-3 inhibitors for treating allergic disorders
|
US6555547B1
(en)
|
2000-02-28 |
2003-04-29 |
Cell Pathways, Inc. |
Method for treating a patient with neoplasia by treatment with a vinca alkaloid derivative
|
US6569638B1
(en)
|
2000-03-03 |
2003-05-27 |
Cell Pathways, Inc |
Method for screening compounds for the treatment of neoplasia
|
WO2003051849A1
(fr)
*
|
2001-12-19 |
2003-06-26 |
Ube Industries, Ltd. |
Procede de production de quinazoline-4-one et derive de celle-ci
|
WO2003064399A1
(fr)
*
|
2002-01-28 |
2003-08-07 |
Ube Industries, Ltd. |
Procede de production de derive de quinazolin-4-one
|
GB0302882D0
(en)
*
|
2003-02-07 |
2003-03-12 |
Univ Cardiff |
Improvements in or relating to agents for the treatment of cardiovascular dysfunction and weight loss
|
CL2004000409A1
(es)
*
|
2003-03-03 |
2005-01-07 |
Vertex Pharma |
Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu
|
GB0307333D0
(en)
*
|
2003-03-29 |
2003-05-07 |
Astrazeneca Ab |
Therapeutic agent
|
CN1774250A
(zh)
*
|
2003-04-16 |
2006-05-17 |
霍夫曼-拉罗奇有限公司 |
作为治疗诸如类风湿性关节炎的炎性疾病的p38激酶抑制剂的(6-(苯氧基)-吡啶并[3,4-d]嘧啶-2-基)-胺衍生物
|
CN1774425A
(zh)
*
|
2003-04-16 |
2006-05-17 |
霍夫曼-拉罗奇有限公司 |
喹唑啉化合物
|
CN112300082B
(zh)
*
|
2019-07-26 |
2022-04-26 |
暨南大学 |
一种苯基哌嗪喹唑啉类化合物或其药学上可接受的盐、制法与用途
|